




Revista de Psiquiatría y Salud Mental

www.elsevier.es/saludmental



EDITORIAL

Making the most of biomarkers in psychiatry Aprovechar al máximo los biomarcadores en psiquiatría

Benedicto Crespo-Facorro

Hospital Universitario Virgen del Rocío, IBI-S, CSIC, Universidad de Sevilla, CIBERSAM

Received 10 May 2022; accepted 11 May 2022



A biomarker is “a characteristic that is objectively measured and evaluated as an indication of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention”.¹ A critical challenge for psychiatric conditions is to identify objective biomarkers that are derived based on the subjective report of patients.² Valid and replicable central or peripheral biomarkers of brain disorders have long been hampered by clinical heterogeneity, lacking sample size and confounder influence, being therefore their clinical applicability questioned.³ Together with huge advances in the field of brain imaging, the growth in several “omics” and other related fields have been impressive, having rendered key insights on the biological underpinning of psychiatric disorders.⁴

This issue of the *Journal*, focused on imaging and molecular biomarkers, presents relevant new findings that add to our growing knowledge and that provide us with new ideas about mechanisms, pathophysiological pathways, and treatment approaches.

Two original research articles in this issue^{5,6} are accompanied by two outstanding systematic reviews on structural and functional neuroimaging biomarkers^{7,8}. The meta-analysis by Soldevila-Matías et al.,⁷ examining cross-sectional fMRI studies comparing neural responses to cognitive tasks between first episode psychosis and healthy controls shows significant hypoactivation in the insula, precuneus and striatum. Importantly, the data from this study do not demonstrate additional frontal hypoactivation during cogni-

tive tasks in FEP. In the article by Rodríguez-Toscano, genetic variability (COMT Val158Met polymorphism) influences prefrontal volume and executive functioning in first episode psychosis individuals.⁵

The search for imaging biomarkers associated to specific clinical symptoms or characteristics has also attracted great research interest in the last decades. In the largest review concerning studies on gray matter volume (GMV) and insight in non-affective psychosis, patients with reduced insight showed decreases GMV in widespread cortical areas and also the metanalytic analysis reveals an association between insular GMV and insight.⁸ Biomarkers emerged from brain imaging analyses have been described in all mental illnesses, including eating disorders. In this issue, a thorough analysis of striatal volumes might be useful to stratifying individuals with anorexia nervosa, bulimia nervosa or eating disorders with comorbid personality disorders.⁶

Animal models are of great value to complement human studies with the aim of building up and testing plausible and valid hypothesis addressing likely biological mechanisms underlying mental illnesses. Fullana and colleagues⁹ aim to understand

the rapid-acting antidepressant effects of ketamine by using a recently described depression animal model based on disturbed astrocyte-based glutamate homeostasis, they provide evidence about the involvement of molecular mechanisms affecting infralimbic cortices and how this pathological mechanism can be reverted by an acute dose of ketamine antidepressant.

<https://doi.org/10.1016/j.rpsm.2022.05.001>

1888-9891/© 2022 Published by Elsevier España, S.L.U. on behalf of SEP y SEPBB.

The challenge of making the most of biomarkers in psychiatry may require to integrate the diversity of biomarkers emerged from cutting-edge neuroscience research (neuroimaging, genomics, molecular, cellular, animal models...) without losing the discipline's sophisticated understanding of behavior and emotion. Persistence and scientific rigor for the long and winding road towards the understanding of abnormal systems in mental illnesses is critical, as neurologists have done.¹⁰ Before the early 2000s, the only certain method to know whether a person had Alzheimer disease was after death through autopsy.

References

1. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther* (2001) 69(3):89-95. doi: 10.1067/mcp.2001.113989.
2. Venkatasubramanian G, Keshavan MS. Biomarkers in Psychiatry - A Critique. *Ann Neurosci*. 2016 Mar;23:3-5, <http://dx.doi.org/10.1159/000443549>. Epub 2016 Mar 11: PMID: 27536015; PMCID: PMC4934408.
3. Fernández-Egea E. Waiting for Godot or the use of biomarkers in clinical practice. *Rev Psiquiatr Salud Ment (Engl Ed)*. 2021 Jul-Sep;14:123-4, <http://dx.doi.org/10.1016/j.rpsmen.2021.07.003>. PMID: 34456029.
4. Hyman SE, Landis SC, Leshner AI. Research Into Brain Disorders as an Example of Targeted Science. *JAMA*. 2016 Oct 25;316:1673-4, <http://dx.doi.org/10.1001/jama.2016.12412>. PMID: 27668392.
5. E. Rodríguez-Toscano, K. Martínez, D. Fraguas et al. , Pre-frontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis, *Revista de psiquiatría y salud mental* (Barcelona), <https://doi.org/10.1016/j.rpsm.2021.11.002>.
6. Molina-Ruiz RM, Looi JCL, Walterfang M, García-Saiz T, Wilkes FA, Liu LL, Velakoulis D, Perera JLC, Diaz-Marsa M. Striatal volumes as potential biomarkers in Eating Disorders: A pilot study. *Rev Psiquiatr Salud Ment (Engl Ed)*. 2020 Jun;S1888-9891:30022-7, <http://dx.doi.org/10.1016/j.rpsm.2020.01.003>. English, Spanish. Epub ahead of print. PMID: 32513624.
7. Soldevila-Matías P, Albajes-Eizaguirre A, Radua J, García-Martí G, Rubio JM, Tordesillas-Gutierrez D, Fuentes-Durá I, Solanes A, Fortea L, Oliver D, Sanjuán J. Precuneus and insular hypoactivation during cognitive processing in first- episode psychosis: Systematic review and meta-analysis of fMRI studies. *Rev Psiquiatr Salud Ment*. 2020 Sep 25;S1888-9891:30100-2. English, Spanish. doi: 10.1016/j.rpsm.2020.08.001. Epub ahead of print. PMID: 32988773.
8. Soldevila-Matías P, Schoretsanis G, Tordesillas-Gutierrez D, Cuesta MJ, de Filippis R, Ayasa-Arriola R, González-Vivas C, Setién-Suero E, Verdolini N, Sanjuán J, Radua J, Crespo-Facorro B. Neuroimaging correlates of insight in non-affective psychosis: A systematic review and meta-analysis. *Rev Psiquiatr. Salud Ment (Engl Ed)*. 2021 Jul 13;S1888-9891:00067-77. English, Spanish. doi: 10.1016/j.rpsm.2021.07.001. Epub ahead of print. PMID: 34271162.
9. M.N. Fullana, V. Paz, F. Artigas et al. , Ketamine triggers rapid antidepressant effects by modulating synaptic plasticity in a new depressive-like mouse model based on astrocyte glutamate transporter GLT-1 knockdown in infralimbic cortex, *Revista de psiquiatría y salud mental* (Barcelona), <https://doi.org/10.1016/j.rpsm.2021.09.002>.
10. Bouwman FH, Frisoni GB, Johnson SC, Chen X, Engelborghs S, Ikeuchi T, Paquet C, Ritchie C, Bozeat S, Quevenno FC, Teunissen C. Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. *Alzheimers Dement (Amst)*. 2022 Apr 27;14:e12314, <http://dx.doi.org/10.1002/dad2.12314>. PMID: 35496374; PMCID: PMC9044123.